3741. The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
作者: Victor Dzau.;Soumya Swaminathan.;Charlotte Baker.;Rick A Bright.;Jose Castillo.;Tan Chorh Chuan.;Ruxandra Draghia-Akli.;Ranna Eardley-Patel.;George F Gao.;Ken Ishii.;Yenew Kebede Tebeje.;Teresa Lambe.;Shingai Machingaidze.;John-Arne Røttingen.;Umesh Shaligram.;Mariângela Simão.;Renu Swarup.;Jean-Francois Toussaint.;Niteen S Wairagkar.
来源: Lancet. 2023年402卷10412期1507-1510页 3743. Increasing compliance with international pandemic law: international relations and new global health agreements.
作者: Matthew M Kavanagh.;Clare Wenham.;Elize Massard da Fonseca.;Laurence R Helfer.;Elvin Nyukuri.;Allan Maleche.;Sam F Halabi.;Adi Radhakrishnan.;Attiya Waris.
来源: Lancet. 2023年402卷10407期1097-1106页
Across multiple pandemics, global health governance institutions have struggled to secure the compliance of states with international legal and political commitments, ranging from data sharing to observing WHO guidance to sharing vaccines. In response, governments are negotiating a new pandemic treaty and revising the International Health Regulations. Achieving compliance remains challenging, but international relations and international law research in areas outside of health offers insights. This Health Policy analyses international relations research on the reasons why states comply with international law, even in the absence of sanctions. Drawing on human rights, trade, finance, tobacco, and environmental law, we categorise compliance mechanisms as police patrol, fire alarm, or community organiser models. We show that, to date, current and proposed global health law incorporates only a few of the mechanisms that have shown to be effective in other areas. We offer six specific, politically feasible mechanisms for new international agreements that, together, could create compliance pressures to shift state behaviour.
3744. Home-based monitoring of ovulation to time frozen embryo transfers in the Netherlands (Antarctica-2): an open-label, nationwide, randomised, non-inferiority trial.
作者: Tjitske Zaat.;Jan-Peter de Bruin.;Mariëtte Goddijn.;Marchien van Baal.;Sofie Benneheij.;Monique Brandes.;Frank Broekmans.;Astrid Cantineau.;Ben Cohlen.;Jeroen van Disseldorp.;Susanne Gielen.;Eva Groenewoud.;Arne van Heusden.;Eugenie Kaaijk.;Carolien Koks.;Corry de Koning.;Nicole Klijn.;Paul van der Linden.;Petra Manger.;Lobke Moolenaar.;Robbert van Oppenraaij.;Quirine Pieterse.;Jesper Smeenk.;Jantien Visser.;Madelon van Wely.;Femke Mol.
来源: Lancet. 2023年402卷10410期1347-1355页
The growing field of assisted reproductive techniques, including frozen-thawed embryo transfer (FET), should lead the way to the best sustainable health care without compromising pregnancy chances. Correct timing of FET is crucial to allow implantation of the thawed embryo. Nowadays, timing based on hospital-controlled monitoring of ovulation in the natural cycle of a woman is the preferred strategy because of the assumption of favourable fertility prospects. However, home-based monitoring is a simple method to prevent patient travel and any associated environmental concerns. We compared ongoing pregnancy rates after home-based monitoring versus hospital-controlled monitoring with ovulation triggering.
3745. Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study.
作者: Raj R Makkar.;Samir Kapadia.;Tarun Chakravarty.;Robert J Cubeddu.;Tsuyoshi Kaneko.;Paul Mahoney.;Dhairya Patel.;Aakriti Gupta.;Wen Cheng.;Susheel Kodali.;Deepak L Bhatt.;Michael J Mack.;Martin B Leon.;Vinod H Thourani.
来源: Lancet. 2023年402卷10412期1529-1540页
With increasing numbers of patients undergoing transcatheter aortic valve replacement (TAVR), data on management of failed TAVR, including repeat TAVR procedure, are needed. The aim of this study was to assess the safety and efficacy of redo-TAVR in a national registry.
3751. Childhood nephrotic syndrome.
Idiopathic nephrotic syndrome is the most common glomerular disease in children. Corticosteroids are the cornerstone of its treatment, and steroid response is the main prognostic factor. Most children respond to a cycle of oral steroids, and are defined as having steroid-sensitive nephrotic syndrome. Among the children who do not respond, defined as having steroid-resistant nephrotic syndrome, most respond to second-line immunosuppression, mainly with calcineurin inhibitors, and children in whom a response is not observed are described as multidrug resistant. The pathophysiology of nephrotic syndrome remains elusive. In cases of immune-mediated origin, dysregulation of immune cells and production of circulating factors that damage the glomerular filtration barrier have been described. Conversely, up to a third of cases of steroid-resistant nephrotic syndrome have a monogenic origin. Multidrug resistant nephrotic syndrome often leads to kidney failure and can cause relapse after kidney transplant. Although steroid-sensitive nephrotic syndrome does not affect renal function, most children with steroid-sensitive nephrotic syndrome have a relapsing course that requires repeated steroid cycles with significant side-effects. To minimise morbidity, some patients require steroid-sparing immunosuppressive agents, including levamisole, mycophenolate mofetil, calcineurin inhibitors, anti-CD20 monoclonal antibodies, and cyclophosphamide. Close monitoring and preventive measures are warranted at onset and during relapse to prevent acute complications (eg, hypovolaemia, acute kidney injury, infections, and thrombosis), whereas long-term management requires minimising treatment-related side-effects. A subset of patients have active disease into adulthood.
|